Lu Xu

ORCID: 0000-0002-7359-7683 · 2 papers in corpus

article 2026

FGFR2-responsive self-assembled hydrogel releases its inhibitor to suppress the progression of endometriosis

Journal of controlled release : official journal of the Controlled Release Society ·doi:10.1016/j.jconrel.2026.115007

Fibroblast growth factor receptor 2 (FGFR2) has emerged as a highly promising therapeutic target due to its critical role in the pathogenesis and progression of endometriosis. To date, a variety of FGFR2 inhibitors have exhibited remarkable…

review 2018

Catechol-O-methyltransferase 158G/A polymorphism and endometriosis/adenomyosis susceptibility: A meta-analysis in the Chinese population

Journal of cancer research and therapeutics ·doi:10.4103/0973-1482.188439

PURPOSE: An association between catechol-O-methyltransferase (COMT) 158G/A polymorphism and endometriosis/adenomyosis susceptibility has been reported in the previous studies, but the results were inconsistent. This study was conducted to e…